Sensei Biotherapeutics (SNSE) Announces 1:20 Reverse Share Split

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on May 21, 2025, with the final ratio subsequently determined by the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Tuesday, June 17, 2025 under the Company's existing trading symbol "SNSE" with the new CUSIP number 81728A207.

At the effective time of the Reverse Stock Split, every 20 shares of the Company's issued and outstanding common stock will be automatically reclassified and combined into 1 share of common stock without any change in the par value per share. This will reduce the number of issued and outstanding shares of common stock from approximately 25.2 million shares to approximately 1.3 million shares. The Reverse Stock Split will proportionately reduce the number of authorized shares of the Company's common stock from 250,000,000 shares to 12,500,000 shares. Proportionate adjustments will be made to the conversion and exercise prices of the company’s outstanding stock options, restricted stock unit awards, warrants and to the number of shares issued and issuable under the Company’s equity incentive plans.

Fractional shares will not be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will be entitled to receive a cash payment. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity securities, except for any adjustments for fractional shares.

Equiniti Trust Company, LLC is acting as the exchange agent and transfer agent for the Reverse Stock Split. Stockholders holding their shares electronically are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker or other nominee will have their positions adjusted to reflect the Reverse Stock Split and will receive payment for any fractional shares in accordance with their respective bank's, broker's, or nominee's particular processes.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
• Cytek faces $56M damages award in Beckman Coulter patent case